Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Other Aug 09 | 2021Viatris and Senseonics Q2 '21 Earnings Updates; Forxiga CKD EU Approval; GoodRx and BI Patient Access Initiative; Diamyd EU Patent Granted; New Glooko CTOPurchase Blast
$599
Posted in: Glucagon, Insulin Delivery, Other Aug 06 | 2021Xeris, Amarin, Regeneron, and BD Q2 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Aug 05 | 2021Omnipod 5 Delayed; Insulet, Provention Bio, and Bayer Q2 '21 Earnings UpdatesPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Aug 04 | 2021Tandem, Ionis, Esperion, and Amgen Q2 '21 Earnings Updates; Dario Gains National Digital Behavioral Health ContractPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Aug 04 | 2021Wegovy Launch Impresses; Guidance Raised; Novo Q2 '21 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Other Aug 02 | 2021Libre 2 iOS App Cleared in US; Novartis Pelacarsen CVOT Reaches 50% EnrollmentPurchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, Other, SGLT2i Jul 30 | 2021Lexicon, Merck, and Intercept Q2 '21 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Jul 29 | 2021Semglee (Bs-glargine) Receives US Interchangeability; Sanofi Q2 '21 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Other Jul 28 | 2021Lifescan and Noom Expand Partnership; Supersapiens Adds Zisser and Ketchell to Leadership Team; Teladoc, Pfizer, and Teva Q2 ’21 Earnings UpdatePurchase Blast
$599
Posted in: Other Jul 27 | 2021AZ and Regeneron Collaborate on Obesity Treatment DevelopmentPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Jul 23 | 2021Bydureon BCise US Pediatric Approval; Biocon FY Q1 ’22 (CY Q2 ’21) Earnings Update; Afrezza Pediatric Ph3 Trial ObservedPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jul 22 | 2021Abbott, Roche, and Adocia Q2 '21 Earnings UpdatesPurchase Blast$599
Posted in: DPP-IVi, Other, SGLT2i Jul 21 | 2021Leqvio PDUFA Date Disclosed; Verquvo EC approval; Ph1b Trial to Delay the Onset or Progression of T1DM Meets Primary Endpoint; Novartis and J&J Q2 '21 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Glucagon, Insulin Delivery, Other Jul 20 | 2021Ascensia Launches Patient Assistance Program for Eversense; Dario Digital Health Contract; Xeris EU Distribution Agreement for Ogluo; Medtronic Extended Wear Infusion Set 510(k) Clearance; Nimium Partnership for G3PP Activator Development; TempraMed Launches Insulin Cooler CapPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Other, SGLT2i Jul 19 | 2021Removal of Forxiga T1DM Indication? Generic Sitagliptin Up for Opinion?; July 19-22 CHMP AgendaPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
